Abstract
Most of Non-Small-Cell lung cancer (NSCLC) patients actually receive an immune checkpoint inhibitor (ICP) as first line treatment. Therapeutic alternatives at progression are limited and rechallenge with ICI may present a major therapeutic opportunity. Prior identification of patients who could benefit from this strategy remains an open question. It has previously been shown that inflammation scores can identify patients who respond to ICP. Their predictive role in rechallenged patients have never been explored.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call